Released on = June 27, 2006, 9:08 am

Press Release Author = Digital Healthcare

Industry = Healthcare

Press Release Summary = Digital Healthcare is pleased to announce the use of its
innovative Clinical Trials iP® software in a pioneering study involving Verteporfin
Photodynamic Therapy (VPDT) for the treatment of "wet" Age-Related Macular
Degeneration (AMD).

Press Release Body = FOR IMMEDIATE RELEASE

Baltimore, MD. June 27, 2006. Digital Healthcare is pleased to announce the use of
its innovative Clinical Trials iP® software in a pioneering study involving
Verteporfin Photodynamic Therapy (VPDT) for the treatment of "wet" Age-Related
Macular Degeneration (AMD). This innovative software system was developed by
Digital Healthcare, the Baltimore-based clinical imaging and workflow management
company.

The Clinical Trials iP® software is a sophisticated electronic platform that
combines the capacity to handle the huge volumes of imaging data captured to
diagnose and treat "wet" AMD, with an electronic patient care management system.
After reading center staff use the system to import thousands of retinal images,
data can then be electronically transferred to a network of various grading
computers via a secure telemessaging facility.

In a unique partnership with three image reading centers located in The Queen's
University of Belfast, St Paul's Eye Unit, Liverpool and Moorfields Eye Hospital,
London, the company's Clinical Trials iP® software will enable healthcare staff to
analyze digital images of the retina gathered from over 3,000 patients per annum,
over the next four years, in 50 regional eye units throughout the United Kingdom.

The results from this study will be used to measure the effectiveness of a
specialist drug and laser therapy (Verteporfin Photodynamic Therapy) as a treatment
for patients suffering from "wet" age-related macular degeneration (AMD), a disease
of the retina that causes blindness in millions worldwide every year.

Professor Usha Chakravarthy of the Centers for Vision Science at Queen's University,
Belfast and Ophthalmic Consultant at Belfast's Royal Hospitals, is one of the lead
clinical investigators involved in delivering treatment for patients with "wet" AMD.
"This is a defining moment in the introduction of new technologies in that it will
provide robust findings on the long-term benefits of verteporfin photodynamic
therapy for the "wet" form of age-related macular degeneration, which afflicts
several thousand older adults annually." said Professor Chakravarthy.

So far, over 5,000 images or angiograms from over 3,000 patients have been submitted
in digital and film formats from the 50 regional treatment centers to the Central
Angiographic Resource Facility (CARF) in Belfast and imported into Digital
Healthcare's Clinical Trials iP® software.

Dr Liam Patton of Queen's University, Belfast and a manager at the CARF, said: "A
key strength of the Clinical Trials iP® software is that it enables images captured
from a variety of sources to be standardized and graded on a common platform. We can
accept angiograms from almost any ophthalmic imaging system in use in the UK, and we
also import film images. We can then use a secure electronic telemessaging system
to transfer the images to the Reading Centers for grading.

The software has eliminated the need to use paper-based systems previously used for
this type of work. During the grading process, there are a multitude of tools
available to assist grading staff in arriving at their decisions, including grids,
circles and measurement tools so that graders can manipulate and compare images.
The software also includes a built-in facility to highlight "urgent" patients so
that they can be promptly graded and their results transferred to a treatment
centers for further investigations."

Nick Nightingale, Applications Director at Digital Healthcare, said: "We are
delighted to have been selected to provide the software for this groundbreaking
study that will generate vital information to improve treatments for patients
suffering from AMD, and which could also serve as a model for the assessment of new
healthcare technologies.

###

About Digital Healthcare, Inc:
Based in Baltimore, Maryland with a Midwest office in Madison, Wisconsin, Digital
Healthcare develops advanced imaging and workflow technologies for a range of
healthcare applications. Digital Healthcare designed a rapid applications
development platform based on Microsoft .NET connected technologies framework called
iP® and the company now offers products in Clinical Ophthalmology, Remote Retinal
Diagnostic Imaging and Digital Reading Centers. The company counts several major US
defense organizations and several leading academic institutions among its early
adopters. Digital Healthcare's parent company is based in Cambridge, England, and
was formed as a management buyout from Perkin Elmer Life Sciences (NYSE: PKI) in
1999.

For more information, please contact the following:
Media Contact: Monica L. Bush - mlb@digital-healthcare.com
Technical Contact: Tony Dolezal - tjd@digital-healthcare.com
CEO: Gerry Skews - gns@digital-healthcare.com
Website: www.digital-healthcare.com


Web Site = http://www.digital-healthcare.com

Contact Details = Monica L. Bush
Media Coordinator
Digital Healthcare, Inc.
1000 Painters Mill Road, Ste. 730
Owings Mills, Maryland 21244
P: 410.654.8954 F: 410.654.8907
Email: mlb@digital-healthcare.com
Web: www.digital-healthcare.com